"Rational hope" in the early treatment of Parkinson's disease.
Identifieur interne : 001709 ( PubMed/Curation ); précédent : 001708; suivant : 001710"Rational hope" in the early treatment of Parkinson's disease.
Auteurs : T L Sourkes [Canada]Source :
- Canadian journal of physiology and pharmacology [ 0008-4212 ] ; 1999.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Apomorphine, Aporphines, Harmine, Levodopa, Monoamine Oxidase Inhibitors, Parasympatholytics.
- drug therapy : Parkinson Disease.
- Humans.
Abstract
The drug treatment of Parkinson's disease since the original description of the malady in 1817 is described. Consideration is given to the historic use of alkaloids of the belladonna, harmala, and aporphine families, and of amphetamine. The introduction of the L-dopa treatment is described. The modes of action of the various drugs employed in the past as well as those in current use are described in the context of knowledge of the functioning of the nigrostriatal tract.
PubMed: 10537223
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001709
Links to Exploration step
pubmed:10537223Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">"Rational hope" in the early treatment of Parkinson's disease.</title><author><name sortKey="Sourkes, T L" sort="Sourkes, T L" uniqKey="Sourkes T" first="T L" last="Sourkes">T L Sourkes</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, McGill University, Montréal, QC, Canada. MBD5@musica.mcgill.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, McGill University, Montréal, QC</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10537223</idno><idno type="pmid">10537223</idno><idno type="wicri:Area/PubMed/Corpus">001709</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001709</idno><idno type="wicri:Area/PubMed/Curation">001709</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001709</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">"Rational hope" in the early treatment of Parkinson's disease.</title><author><name sortKey="Sourkes, T L" sort="Sourkes, T L" uniqKey="Sourkes T" first="T L" last="Sourkes">T L Sourkes</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry, McGill University, Montréal, QC, Canada. MBD5@musica.mcgill.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, McGill University, Montréal, QC</wicri:regionArea></affiliation></author></analytic><series><title level="j">Canadian journal of physiology and pharmacology</title><idno type="ISSN">0008-4212</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apomorphine (therapeutic use)</term><term>Aporphines (therapeutic use)</term><term>Harmine (therapeutic use)</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Parasympatholytics (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Apomorphine</term><term>Aporphines</term><term>Harmine</term><term>Levodopa</term><term>Monoamine Oxidase Inhibitors</term><term>Parasympatholytics</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The drug treatment of Parkinson's disease since the original description of the malady in 1817 is described. Consideration is given to the historic use of alkaloids of the belladonna, harmala, and aporphine families, and of amphetamine. The introduction of the L-dopa treatment is described. The modes of action of the various drugs employed in the past as well as those in current use are described in the context of knowledge of the functioning of the nigrostriatal tract.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10537223</PMID><DateCreated><Year>1999</Year><Month>11</Month><Day>04</Day></DateCreated><DateCompleted><Year>1999</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0008-4212</ISSN><JournalIssue CitedMedium="Print"><Volume>77</Volume><Issue>6</Issue><PubDate><Year>1999</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Canadian journal of physiology and pharmacology</Title><ISOAbbreviation>Can. J. Physiol. Pharmacol.</ISOAbbreviation></Journal><ArticleTitle>"Rational hope" in the early treatment of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>375-82</MedlinePgn></Pagination><Abstract><AbstractText>The drug treatment of Parkinson's disease since the original description of the malady in 1817 is described. Consideration is given to the historic use of alkaloids of the belladonna, harmala, and aporphine families, and of amphetamine. The introduction of the L-dopa treatment is described. The modes of action of the various drugs employed in the past as well as those in current use are described in the context of knowledge of the functioning of the nigrostriatal tract.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sourkes</LastName><ForeName>T L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montréal, QC, Canada. MBD5@musica.mcgill.ca</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can J Physiol Pharmacol</MedlineTA><NlmUniqueID>0372712</NlmUniqueID><ISSNLinking>0008-4212</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001060">Aporphines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010276">Parasympatholytics</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>4FHH5G48T7</RegistryNumber><NameOfSubstance UI="D006247">Harmine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O0TGI865QO</RegistryNumber><NameOfSubstance UI="C083807">bulbocapnine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001060" MajorTopicYN="N">Aporphines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006247" MajorTopicYN="N">Harmine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010276" MajorTopicYN="N">Parasympatholytics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>60</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>10</Month><Day>28</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>10</Month><Day>28</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10537223</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001709 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001709 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:10537223
|texte= "Rational hope" in the early treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:10537223" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |